Treating Hyperinsulinemia with *Momordica charantia*

Frank Comhaire

Department of Endocrinology, Ghent University Hospital, Belgium

*Corresponding author:* Prof. Frank Comhaire, Brakelmeersstraat, 18 B9830 Sint Martens-Latem, Belgium, Tel: +32 475 618 555; E-mail: Frank@comhaire.com

Rec Date: May 15, 2015; Acc Date: June 30, 2015; Pub Date: July 5, 2015

Copyright: © 2015 Comhaire. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Abstract**

**Objectives:** To assess the efficacy of a novel nutraceutical mainly containing the extract of bitter gourd (*Momordica charantia*) and α-lipoic acid for the treatment of patients with hyperinsulinemia.

**Methods:** Pilot prospective open-label cohort trial including 11 patients with hyperinsulinemia due to insulin resistance. The concentrations of insulin, C-peptide, glucose, haemoglobin A1c, total cholesterol, triglycerides, gamma-glutamyl transferase, and C-reactive protein were measured in blood take between 3 and 4 hours after dinner.

**Results:** One and 4 months after initiation of treatment there was a significant decrease of the concentrations of Insulin (to average 25% of initial value), C-peptide (to average 44% of initial value), glucose, hemoglobin A1c and gamma-glutamyl tranpeptidase.

**Clinical significance:** Treatment of patients with hyperinsulinemia, with or without diabetes or metabolic syndrome, using a novel nutraceutical containing *Momordica charantia* and α-lipoic acid dramatically reduced insulin resistance and may have improved non-alcoholic fatty liver disease.

**Keywords:** Insulin resistance; Hyperinsulinemia; *Momordica charantia*; Bitter gourd; Alpha lipoic acid; Nutraceutical

**Introduction**

Insulin resistance is the common denominator of the metabolic syndrome and obesity, pre-diabetes, and type 2 diabetes. It induces compensatory insulin hyperscretion. Impaired insulin sensitivity is frequent during statin treatment [1]. Hyperinsulinemia has been associated with prostate- [2] and breast cancer [3,4], and with non-alcoholic fatty liver disease.

In addition to live style adjustment and appropriate diet, Metformin is considered the first-line treatment of hyperinsulinemia. As efficient as this treatment may be, it is not devoid of serious side effects such as lactic acidosis, renal toxicity, and gastrointestinal discomfort.

There are several non-pharmaceutical agents that counteract insulin resistance and may decrease hyperinsulinemia, of which the extract of *Momordica charantia* (bitter gourd or bitter melon) is well-known. Its mechanisms of action include increased phosphorylation of acetyl-CoA carboxylase and AMP-activated protein kinase (AMPK) [5], reduction of lipogenesis, enhanced thermogenesis and lipolysis [6]. The extract down-regulates the expression of peroxisome proliferator-activated receptor (PPAR)-gamma, nuclear factor kappaB (NF-kB), and interferon-gamma in heart tissue, with cardio-protective effect thanks to reduction of inflammation [7]. In addition, Momordica exerts an interesting endocrine effect where it inhibits the enzyme 11β-hydroxysteroid dehydrogenase type 1, that metabolises the mineralocorticoid cortisol to the glucocorticoid cortisol [8]. There is evidence for increased activity of this enzyme in adipose cells [9], and that this may be an important aetiological factor in the pathogenesis of obesity-associated insulin resistance.

Alpha-lipoic acid is a water soluble anti-oxidant which has been proven to reduce insulin resistance [10] in patients with type 2 diabetes [11] or obese and overweight non-diabetic men [12] and women [13], and it may potentially be used in cardiovascular diseases [14]. Alpha-lipoic acid was shown to improve angiogenesis and bioenergetics in hyperglycemia [15], and to upregulate irisin secretion in adipocytes, protecting against deleterious effects of glucose impairment [16].

The combination of Momordica extract and alpha-lipoic acid was expected to act in synergism because these agents are effective along different molecular pathways.

Here we report the results of an open-label, pilot trial of the treatment of a cohort of patients suffering from hyperinsulinemia, using a novel nutraceutical that combines the extract of *Momordica charantia* with alpha-lipoic acid.

**Materials and Methods**

Eleven consecutive patients consulting at the private clinic of the author and presenting hyperinsulinemia were invited to participate in an open-label, prospective trial using a novel nutraceutical containing 350 mg of the 1:4 extract of *Momordica charantia* and 50 mg alpha-lipoic acid (Cambridge Commodities, UK) in vegicaps (Pharmacy Van Wambreke, Elversele, Belgium)(Belgian patent # 1021188). Patients were requested to take 1 capsule after breakfast and one after dinner. The cohort consisted of 7 women and 4 men aged between 56 to 76 years. One woman was under treatment for type 2 diabetes with Metformin and Glipizide, with insufficient result and elevated haemoglobin A1c concentration. The nutraceutical was added to her initial medication. Patients were already given “healthy diet” recommendations before the initiation of the trial, emphasizing the
importance of reducing sugar and fructose intake. Two patients dropped out for personal reasons, though one patient resumed participation at a later date (data not included).

Before treatment was initiated, blood was taken, and this was repeated after 1 and 4 months of treatment. Blood was taken between 3 and 4 hours after lunch, and analysed for glycemia, haemoglobin A1c, insulin, C-peptide, triglycerides, total cholesterol, gamma glutamyl transpeptidase, and C-reactive protein (CRP) using well-established standard procedures (Anacura laboratory Ltd., Evergem, Belgium).

Results were plotted into the spreadsheet of the MedCalc statistical software (MedCalc Ltd, Ostend, Belgium) and described by means of parametrical (mean, standard deviation) and non-parametrical variables (median, 95% confidence intervals). Individual data of relevant biological markers are also presented in box-and-whisker plots with dots.

The significance of changes over time was assessed using the non-parametrical Wilcoxon’s signed-rank test for paired observations, that is independent of the distribution of the data. The effective P-values of this test are listed.

Results

There was a highly significant correlation between the concentrations of insulin and C-peptide both before treatment (r=0.92, P=0.009) and after 1 month of nutraceutical intake (r=0.80, P=0.029). The results of all measurements are listed in Table 1.

The concentrations of insulin, C-peptide, glycemia, gamma glutamyl transpeptidase and hemoglobin A1c presented a significant decrease (P<0.05) over the observation period (Table 2). Triglycerides, total cholesterol, and C-reactive protein did not change significantly. The individual values of insulin (Figure 1), C-peptide (Figure 2), and gamma glutamyl transpeptidase (Figure 3) are shown in box-and-whisker plots with dots.

Table 1: Time 0 lists the measurements before initiation of treatment. 1 month and 4 month list the measurements after respectively 1 and 4 months of intake of the nutraceutical. Gamma GT stands for gamma glutamyl transpeptidase. Values given are mean and standard deviation (SD), median and 95% confidence interval. Units: Insulin: µU/L; C-peptide: ng/mL; Glycemia: mg/mL; Hemoglobin A1c: %; Triglycerides: mg/dL; total cholesterol: mg/dL, Gamma glutamyl transpeptidase: U/L; C-reactive protein: mg/L.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Time 0 (mean, SD)</th>
<th>Time 0 (median, 95% CI)</th>
<th>1 mth (mean, SD)</th>
<th>1 mth (median, 95% CI)</th>
<th>1 mth (median, 95% CI)</th>
<th>4 mth (median, 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>insulin</td>
<td>75.6 (50.2)</td>
<td>76.8 (39.3-107.4)</td>
<td>41.1 (23.1)</td>
<td>39.9 (18.9-54.9)</td>
<td>18.7 (7.2)</td>
<td>17.7 (10.8-17.8)</td>
</tr>
<tr>
<td>C-peptide</td>
<td>9.38 (2.85)</td>
<td>8.41 (7.00-11.91)</td>
<td>6.27 (1.72)</td>
<td>5.96 (4.85-7.59)</td>
<td>4.19 (1.27)</td>
<td>3.83 (3.45-4.88)</td>
</tr>
<tr>
<td>glycemia</td>
<td>129 (39.1)</td>
<td>127 (99.3-167.1)</td>
<td>105.5 (18.8)</td>
<td>97 (89.0-126.1)</td>
<td>99.0 (27.6)</td>
<td>91.0 (80.2-119.5)</td>
</tr>
<tr>
<td>hemoglobin A1c</td>
<td>6.77 (1.7)</td>
<td>6.30 (5.56-6.21)</td>
<td>6.42 (1.57)</td>
<td>6.00 (5.34-7.26)</td>
<td>6.08 (8.86)</td>
<td>5.9 (5.42-6.70)</td>
</tr>
<tr>
<td>triglycerids</td>
<td>245 (96.6)</td>
<td>241 (176-314)</td>
<td>238 (137)</td>
<td>248 (68-408)</td>
<td>270 (114)</td>
<td>218 (130-412)</td>
</tr>
<tr>
<td>total cholesterol</td>
<td>209 (47.0)</td>
<td>202 (157-242)</td>
<td>208 (40.9)</td>
<td>202 (166-245)</td>
<td>229 (65,7)</td>
<td>210 (179-333)</td>
</tr>
<tr>
<td>gamma GT</td>
<td>42.3 (18.5)</td>
<td>41.5 (23.3-55.6)</td>
<td>36.4 (13.4)</td>
<td>37.0 (24.0-48.8)</td>
<td>31.8 (11.1)</td>
<td>34.0 (19.4-42.2)</td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>3.67 (2.43)</td>
<td>3.70 (1.24-5.89)</td>
<td>2.67 (1.98)</td>
<td>2.1 (0.19-5.13)</td>
<td>4.72 (2.96)</td>
<td>4.65 (0.01-9.44)</td>
</tr>
</tbody>
</table>

Table 2: P-values of the comparison between values measured at different time intervals, using the non-parametrical Wilcoxon signed-rank test for paired observations.
The concentrations of insulin (Figure 1), C-peptide (Figure 2), glycemia, gamma glutamyl transpeptidase (Figure 3) and hemoglobin A1c presented a significant decrease (P<0.05) over the observation (Table 2). Triglycerids, total cholesterol, and C-reactive protein did not present significant changes.

**Figure 1**: Box and whisker plots of Insulin concentration (in µU/L, on the vertical axis) at time 0, before initiation of treatment, after 1 month, and after 4 months of nutraceutical intake. The median is given, the boxes indicate the 25th and 75th percentile, and the whiskers correspond to the 5th and 95th percentile. Individual data are plotted.

**Figure 2**: Box and whisker plot of C-peptide (in ng/mL). The median is given, the boxes indicate the 25th and 75th percentile, and the whiskers correspond to the 5th and 95th percentile. Individual data are plotted.

**Figure 3**: Box and whisker plot of gamma glutamyltranspeptidase (in U/L). The median is given, the boxes indicate the 25th and 75th percentile, and the whiskers correspond to the 5th and 95th percentile. Individual data are plotted.

**Discussion**

The benefit of *Momordica charantia* has been amply documented for the treatment of type 2 diabetes. It increases sensitivity of the insulin receptor [17], reduces insulin resistance and hyperinsulinemia, with favourably influence on the metabolic syndrome [18] and diabetes [19] in humans.

Obesity promotes prostate cancer [20] which has been related to hyperinsulinemia and insulin resistance [2, 21-23]. *Momordica* extract exerts chemo-protective effect against prostate cancer cells *in vitro* [24,25]. Its insulin-reducing effect may decrease neoplastic growth of the prostate in humans [26]. Also, insulin resistance has been found to impair cognitive function [27] and to promote Alzheimer disease [28]. The association between lower urinary tract symptoms (LUTS) and risk of dementia [29] may relate to hyperinsulinemia as common pathogenic factor. Therefore, decreasing insulin resistance may possibly contribute to the prevention of brain damage.

Little is known about the efficiency of *Momordica*, associated with alpha-lipoic acid on hyperinsulinemia in patients, some of whom satisfy the criteria for the diagnosis of metabolic syndrome or with diabetes type 2. Clamp tests were not performed, but the recommendations of Jones and Hattersley [30] were implemented by measuring insulin and C-peptide in blood taken between 3 and 4 hours after dinner.

Under these circumstances all cases presented an important improvement of their metabolic status, with persistent reduction of the hyperinsulinemia and other biological markers. Serum gamma-glutamyl transpeptidase concentration was reported to distinguish non-alcoholic fatty liver disease at high risk [31,32] particularly in patients with the metabolic syndrome [33]. The decreased gamma-glutamyl transpeptidase activity observed during nutraceutical intake suggests a beneficial effect on non-alcoholic fatty liver disease [34,35], since this was shown to be associated with histologic improvement [36], and it may reduce the risk of developing type-2 diabetes [37].

There were no side effects, and gastro-intestinal tolerance was excellent. Vital signs and blood tests for renal function, and peripheral red and white blood cells count remained unchanged. Two cases mentioned weight loss over 10%, which they were unable to attain before initiation of treatment, even though adhering to the same diet.

Our findings underscore the benefit of nutraceutical treatment using the novel formulation in patients suffering from hyperinsulinemia, which should stimulate further research into its
References


